Dr. Yajun Li 李亚军
Chief Physician
Department of Medical Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Precision diagnosis and comprehensive treatment of lymphoma and multiple myeloma, including chemotherapy, targeted therapy, immunotherapy, autologous hematopoietic stem cell transplantation, and CAR-T cell therapy. Specializes in NK/T-cell lymphoma and tumor-related thrombocytopenia.
Dr. Li is Deputy Director and Chief Physician at Hunan Cancer Hospital. Earned a PhD in Oncology from Sun Yat-sen University Cancer Center in 2013. Leads five provincial and municipal research projects. Serves on the editorial board of Tumor Pharmacy. Participated in over 80 clinical trials for lymphoma and myeloma drugs. Published more than 50 papers in journals such as Lancet Oncology and Blood Cancer Journal.
Professional roles
- Member, Lymphoma Professional Committee, China Anti-Cancer Association
- Member, Youth Committee, CSCO Anti-Lymphoma Alliance
- Standing Committee Member, Lymphoma Professional Committee, China Health Care Association for the Elderly
- Vice Chair, Youth Committee, Lymphoma Professional Committee, Hunan Anti-Cancer Association
Name order: in Chinese the family name comes first (Li Yajun). Papers usually list the name as Yajun Li or Li Y.
Selected publications
42 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Leukemia, 2024 (first author): Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK/T-cell lymphoma. PubMed 38783159
- Int J Gen Med, 2021 (first author): Survival Analysis of Hepatosplenic T Cell Lymphoma: A Population-Based Study Using SEER. PubMed 34819748
- Blood Res, 2020 (first author): HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases. PubMed 32269975
- Chin J Cancer, 2017 (first author): Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma, nasal type: a triple-center study. PubMed 28756771
- Oncotarget, 2017 (first author): Increased body mass index is associated with improved overall survival in extranodal natural killer/T-cell lymphoma, nasal type. PubMed 28002803
- Ann Hematol, 2015 (first author): High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma. PubMed 25146008
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion